Maxpro Capital Acquisition Corp. (JMAC) Shareholders Approve Apollomics Deal
by Marlena Haddad on 2023-03-21 at 4:52pm

Maxpro Capital (NASDAQ:JMAC) announced this afternoon that its shareholders have approved its combination with biopharmaceutical firm Apollomics.

An aggregate of 10,804,097 shares of Maxpro’s common stock were present at yesterday’s special meeting. Holders of 8,024,976 shares of common stock approved the business combination, but the deal faced a bit of pushback with 2,779,121 shares voting against it.

In connection with the transaction, holders of 10,270,060 shares, or 99.228% of Maxpro’s trust, exercised their right to redeem their shares. Following the redemptions, the SPAC is left with 79,940 shares remaining.

The parties have not yet disclosed when the deal will be completed, but the combined company is expected to trade on the Nasdaq under the symbol “APLM” once it closes.

Maxpro Capital announced its $899 million deal with Apollomics in September 2022. The Foster City, California-based company is developing a line of drug candidates to treat rare cancers with clinical processes nearing completion in both the US and Chinese treatment markets.


ADVISORS

  • ARC Group Limited is acting as financial advisor to Maxpro.
  • EF Hutton is acting as capital market advisor to Maxpro.
  • White & Case LLP is acting as legal counsel to Apollomics.
  • Nelson Mullins Riley & Scarborough LLP is acting as legal counsel to Maxpro.
  • Marshall & Stevens Transaction Advisory Services LLC is acting as the fairness opinion provider to the board of directors of Maxpro.

 

Recent Posts
by Kristi Marvin on 2024-06-15 at 11:30am

Terms Tracker for the Week Ending June 14, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. It was all about the new IPOs and new SPACs getting filed again this week. Cantor managed to price one new IPO on Monday night...

by Nicholas Alan Clayton on 2024-06-14 at 1:20pm

Launch One (NASDAQ:LPAAU) has continued Cantor Fitzgerald’s streak of underwriting new SPAC S-1s with nearly its whole offering already spoken for by non-managing sponsors, in this case a $200 million IPO to hunt in the Life Sciences industry. This SPAC’s non-managing sponsors have expressed interest in 22,690,820 of its units (assuming the full over-allotment option...

by Nicholas Alan Clayton on 2024-06-14 at 8:35am

At the SPAC of Dawn June is now on pace to more than double the issuance of new SPACs with its fifth filed yesterday while May saw seven new SPACs filed. Overall, there have been 21 new S-1 filings on the year and 12 IPOs. By comparison, there had been just 13 new SPACs filed...

by Nicholas Alan Clayton on 2024-06-13 at 12:39pm

After years of ratcheting up financial incentives to make and buy EVs, the world’s trade blocks are now rushing to stack up protectionist barriers, leaving the recent string of EV de-SPACs divided between them. Hong Kong-based EV maker Thunder Power may be the latest to join this increasingly complicated sector as Feutune Light (NASDAQ:FLVF) shareholders...

by Nicholas Alan Clayton on 2024-06-13 at 8:40am

At the SPAC of Dawn No news is good news appears to be the SPAC takeaway from CPI and Fed comments double-header yesterday. With inflation steady and one rate cut still expected for 2024, SPACs and de-SPACs in volatile sectors may now have a somewhat clearer flight path through the rest of the year. Fashion...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved